# US 10,865,209 B2 · Process for preparing temozolomide and an intermediary

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,865,209 B2
- Document ID: US10865209B2
- Status: Granted
- Kind: B2
- Application number: 16/471,524
- Filed: 2017-12-19
- Published: 2020-06-18
- Granted: 2020-12-15
- Earliest claimed: 2016-12-20
- Assignees: Cristalia Produtos Quimicos Farmaceuticos Ltda.
- Applicants: CristáLia Produtos QuíMicos FarmacêUticos Ltda
- Inventors: Ogari Pacheco; Vincenzo De Sio; Murilo Massoni; Leandro Camargo
- Web page: https://patentgrep.com/patent/US10865209B2

## CPC

- A61P 35/00: Antineoplastic agents
- C07D 487/04: Ortho-condensed systems
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates to an efficient and industrially advantageous process for preparing temozolomide and the carbamoyl-AICA intermediate through the use of N-methyl carbamoylimidazole in a good overall yield and high purity.

## Claims

### Claim 1

A process for preparing temozolomide, comprising the following steps:
(a) Reacting AICA base with N-methyl carbamoylimidazole to provide carbamoyl-AICA;
(b) Reacting carbamoyl-AICA with an alkali or alkaline earth metal nitrite in the presence of an acid to provide temozolomide.

### Claim 2 (depends on 1)

The process according to claim 1, wherein step (a) is carried out in an aprotic polar organic solvent.

### Claim 3 (depends on 2)

The process according to claim 2, wherein the solvent is acetonitrile or tetrahydrofuran.

### Claim 4 (depends on 3)

The process according to claim 3, wherein the solvent is acetonitrile.

### Claim 5 (depends on 1)

The process according to claim 1, wherein the alkali metal nitrite in step (b) is sodium nitrite added to the reaction medium in solid form.

### Claim 6 (depends on 1)

The process according to claim 1, wherein the acid in step (b) is tartaric acid.

### Claim 7 (depends on 1)

The process according to claim 1, which further comprises purifying temozolomide from the reaction (b), and crystallizing the temozolomide.

### Claim 8 (depends on 1)

The process according to claim 1, wherein the N-methyl carbamoylimidazole of step (a) is prepared from the reaction of carbonyldiimidazole with methylamine hydrochloride in a mixture of acetonitrile and dimethylformamide.

### Claim 9

A process for preparing temozolomide, comprising the following steps:
(a) Reacting carbonyldiimidazole with methylamine hydrochloride in a mixture of acetonitrile and dimethylformamide to obtain N-methylcarbamoylimidazole;
(b) Reacting AICA base with N-methyl carbamoylimidazole in an aprotic polar organic solvent to provide carbamoyl-AICA;
(c) Reacting carbamoyl-AICA with sodium nitrite, added to the reaction medium in solid form, in the presence of a tartaric acid solution and, at the end of the reaction, heating the reaction mixture to 60° C. and filtering to provide temozolomide and azahypoxanthine in a ratio of 60:40;
(d) Purifying temozolomide through a chromatographic column filled with adsorbent polymer resin containing a carbon capsule coupled to the end of the column to provide a clarified solution of temozolomide, and crystallizing temozolomide from the clarified solution.

### Claim 10 (depends on 9)

The process according to claim 9, wherein the aprotic polar organic solvent in step (b) is acetonitrile or tetrahydrofuran.

### Claim 11 (depends on 10)

The process according to claim 10, wherein the solvent is acetonitrile.

### Claim 12 (depends on 9)

The process according to claim 9, wherein, after said chromatography in step (d), the clarified temozolomide solution is concentrated at 60° C. to between 30 and 40 volumes relative to the theoretical weight of temozolomide, and thereafter cooled to provide crystals of temozolomide monohydrate.

### Claim 13 (depends on 9)

The process according to claim 9, wherein after said chromatography in step (d), the clarified temozolomide solution is concentrated at 60° C. to up to about 5 volumes relative to the theoretical weight of temozolomide, combined with 15 volumes of acetone, and thereafter cooled to provide crystals of temozolomide form III.

### Claim 14 (depends on 12)

The process according to claim 12, wherein the temozolomide monohydrate is optionally suspended in a 1:3 ratio mixture of water and acetone, heated to 60° C. and then cooled to provide temozolomide form III.

### Claim 15

A process for preparing carbamoyl-AICA comprising the reaction between AICA base and N-methyl carbamoylimidazole in an aprotic polar organic solvent.

### Claim 16 (depends on 15)

The process according to claim 15, wherein the solvent is acetonitrile or tetrahydrofuran.

### Claim 17 (depends on 16)

The process according to claim 16, wherein the solvent is acetonitrile.

### Claim 18 (depends on 1)

The process according to claim 1, wherein the step (a) is performed without the addition of a tertiary amine base.

### Claim 19 (depends on 9)

The process according to claim 9, wherein the step (b) is performed without the addition of a tertiary amine base.

### Claim 20 (depends on 15)

The process according to claim 15, wherein the reaction is performed without the addition of a tertiary amine base.

### Claim 21 (depends on 1)

The process according to claim 1, further comprising, at the end of the reaction, raising the temperature of the reaction mixture (b) to from 60° C. to 65° C.
